

# Hertzel C Gerstein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1471997/publications.pdf>

Version: 2024-02-01

454  
papers

71,851  
citations

1530

106  
h-index

601

260  
g-index

474  
all docs

474  
docs citations

474  
times ranked

47005  
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus report: Definition and interpretation of remission in type 2 diabetes. <i>Diabetic Medicine</i> , 2022, 39, e14669.	1.2	15
2	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1-9.	1.8	32
3	Myopia and Early-Onset Type 2 Diabetes: A Nationwide Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e663-e671.	1.8	3
4	Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial. <i>Diabetologia</i> , 2022, 65, 206-215.	2.9	31
5	Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial. <i>Diabetes Care</i> , 2022, 45, 178-185.	4.3	8
6	Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. <i>Circulation</i> , 2022, 145, 565-574.	1.6	59
7	Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the <sc>REWIND</sc> randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 704-712.	2.2	4
8	Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102382.	1.8	22
9	Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. <i>Diabetes Care</i> , 2022, 45, 684-691.	4.3	31
10	HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial. <i>Diabetes Care</i> , 2022, , .	4.3	4
11	Identification of genetic effects underlying type 2 diabetes in South Asian and European populations. <i>Communications Biology</i> , 2022, 5, 329.	2.0	21
12	Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes. <i>Journal of the American Heart Association</i> , 2022, 11, e021327.	1.6	5
13	Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1334-1342.	0.8	16
14	Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3448-e3454.	1.8	2
15	Biomarkers of Prevalent and Incident Cognitive Dysfunction in People with Dysglycemia- Data from the ORIGIN Trial. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-8.	1.2	0
16	Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. <i>Nature Genetics</i> , 2022, 54, 560-572.	9.4	250
17	Efficacy and safety outcomes of dulaglutide by baseline <sc>HbA1c</sc>: A post hoc analysis of the <sc>REWIND</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1753-1761.	2.2	2
18	Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1434-1441.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Shouldn't Preventing Type 2 Diabetes Also Prevent Its Long-Term Consequences?. <i>Circulation</i> , 2022, 145, 1642-1644.	1.6	2
20	Response to Comment on Koska et al. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. <i>Diabetes Care</i> 2022;44:684-691. <i>Diabetes Care</i> , 2022, 45, e111-e112.	4.3	0
21	Obesity in late adolescence and incident type 1 diabetes in young adulthood. <i>Diabetologia</i> , 2022, 65, 1473-1482.	2.9	18
22	Glucose Intolerance in Pregnancy and Offspring Obesity in Late Adolescence. <i>Diabetes Care</i> , 2022, 45, 1540-1548.	4.3	12
23	Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to <i>iGlarLixi</i> in the <i>LixiLan ONE CAN</i> randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1998-2007.	2.2	4
24	Lixilan ONE CAN: Randomisierte Studie zum Vergleich eines taglichen vs. wochentlichen Titrationsalgorithmus fur den Wechsel von Basalinsulin zur Fixkombination <i>iGlarLixi</i> bei Typ-2-Diabetespatienten in Kanada. <i>Diabetologie Und Stoffwechsel</i> , 2022, , .	0.0	0
25	Response by Lam and Gerstein to Letter Regarding Article, "Efglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial". <i>Circulation</i> , 2022, 146, .	1.6	0
26	Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study. <i>Diabetes Care</i> , 2022, 45, 2152-2155.	4.3	3
27	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. <i>European Heart Journal</i> , 2021, 42, 2565-2573.	1.0	17
28	Effect of Diabetes Health Coaching on Glycemic Control and Quality of Life in Adults Living With Type 2 Diabetes: A Community-Based, Randomized, Controlled Trial. <i>Canadian Journal of Diabetes</i> , 2021, 45, 594-600.	0.4	13
29	Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial. <i>Diabetes Care</i> , 2021, 44, 164-173.	4.3	31
30	Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents. <i>Diabetes Care</i> , 2021, 44, e6-e8.	4.3	8
31	Design and baseline characteristics of the <i>AMPLITUDE-O</i> cardiovascular outcomes trial of efglenatide, a weekly glucagon-like peptide-1 receptor agonist. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 318-323.	2.2	12
32	Diabetes, Brain Infarcts, Cognition, and Small Vessels in the Canadian Alliance for Healthy Hearts and Minds Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e891-e898.	1.8	11
33	Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e34-e44.	1.8	13
34	Stuttering and Incident Type 2 Diabetes: A Population-Based Study of 2.2 Million Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e978-e987.	1.8	4
35	The Relationship Between Glucose Control and Cognitive Function in People With Diabetes After a Lacunar Stroke. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1521-1528.	1.8	9
36	Creating Composite Indices From Continuous Variables for Research: The Geometric Mean. <i>Diabetes Care</i> , 2021, 44, e85-e86.	4.3	8

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1345-1351.	1.8	14
38	Testosterone and sex hormone-binding globulin in dysglycemic women at high cardiovascular risk: A report from the Outcome Reduction with an Initial Glargine Intervention trial. <i>Diabetes and Vascular Disease Research</i> , 2021, 18, 147916412110024.	0.9	6
39	Insulin Therapy: The Discovery That Shaped a Century. <i>Canadian Journal of Diabetes</i> , 2021, , .	0.4	10
40	Association Between Bariatric Surgery and Major Adverse Diabetes Outcomes in Patients With Diabetes and Obesity. <i>JAMA Network Open</i> , 2021, 4, e216820.	2.8	29
41	Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries. <i>JAMA Internal Medicine</i> , 2021, 181, 631.	2.6	68
42	Short-term intensive insulin as induction and maintenance therapy for the preservation of beta-cell function in early type 2 diabetes (<sc>RESET Main</sc>): A 2-year randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1926-1935.	2.2	8
43	Adolescent Thyroid Disorders and Risk for Type 2 Diabetes in Young Adulthood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3426-e3435.	1.8	8
44	95-LB: LixilanONE CAN: Randomized Trial Comparing a Daily vs. Weekly Titration Algorithm for Switching from Basal Insulin to iGlarLixi Fixed-Ratio Combination in People with T2DM in Canada. <i>Diabetes</i> , 2021, 70, 95-LB.	0.3	0
45	677-P: Remission of Type 2 Diabetes following Intensive Treatment with Insulin Glargine, Lixisenatide, Metformin, and Lifestyle Approaches: Results of a Multicenter Randomized Controlled Trial. <i>Diabetes</i> , 2021, 70, 677-P.	0.3	0
46	187-OR: Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes in the ACCORD Trial. <i>Diabetes</i> , 2021, 70, .	0.3	0
47	Asthma in Youth and Early-onset Type 2 Diabetes: A Nationwide Study of 1.72 Million Israeli Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e5043-e5053.	1.8	2
48	NT-proBNP versus routine clinical risk factors as a predictor of cardiovascular events or death in people with dysglycemia â€“ A brief report from the ORIGIN trial. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107928.	1.2	2
49	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, 2438-2444.	4.3	152
50	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 484-490.	5.5	17
51	Economic analysis of a diabetes health coaching intervention for adults living with type 2 diabetes. A single centre evaluation from a community-based randomized controlled trial.. <i>Canadian Journal of Diabetes</i> , 2021, , .	0.4	1
52	Consensus report: definition and interpretation of remission in type 2 diabetes. <i>Diabetologia</i> , 2021, 64, 2359-2366.	2.9	39
53	Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. <i>Cardiovascular Diabetology</i> , 2021, 20, 194.	2.7	29
54	Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2021, 10, e022222.	1.6	38

#	ARTICLE	IF	CITATIONS
55	Cardiovascular and Renal Outcomes with Epeglenatide in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 896-907.	13.9	339
56	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 653-662.	5.5	437
57	Adolescent cognitive function and incident early-onset type 2 diabetes. <i>EClinicalMedicine</i> , 2021, 41, 101138.	3.2	4
58	HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression. <i>Diabetes Care</i> , 2021, 44, 290-296.	4.3	49
59	Lingering Effects of Hyperglycemia in Recently Diagnosed Diabetes During Long-term Follow-up of the DCCT/EDIC and UKPDS Cohorts: More Evidence That Early Control Matters. <i>Diabetes Care</i> , 2021, 44, 2212-2215.	4.3	4
60	Exploring the Experiences of Adults With Type 2 Diabetes on Sodium Glucose Cotransporter 2 Inhibitors. <i>Canadian Journal of Diabetes</i> , 2020, 44, 184-191.	0.4	1
61	Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood. <i>Diabetes Care</i> , 2020, 43, 145-151.	4.3	23
62	Novel Biomarkers for Change in Renal Function in People With Dysglycemia. <i>Diabetes Care</i> , 2020, 43, 433-439.	4.3	8
63	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 106-114.	5.5	77
64	Are large simple trials for dementia prevention possible?. <i>Age and Ageing</i> , 2020, 49, 154-160.	0.7	17
65	Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study. <i>Diabetes Care</i> , 2020, 43, 3094-3101.	4.3	32
66	Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 175.	2.7	1
67	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trial: a post hoc analysis. <i>Cardiovascular Diabetology</i> , 2020, 19, 199.	2.7	14
68	DULAGLUTIDE REDUCES HBA1C IRRESPECTIVE OF ANTIHYPERGLYCEMIC AGENTS, DURATION OF DIABETES, BMI AND WEIGHT LOSS: A POST HOC ANALYSIS FROM THE REWIND TRIAL. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1951.	1.2	0
69	The obesity paradigm in cardiovascular disease: the need for differentiated weight management. <i>European Heart Journal</i> , 2020, 41, 3965-3965.	1.0	2
70	Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial. <i>European Heart Journal</i> , 2020, 41, 2668-2677.	1.0	60
71	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. <i>Lancet Neurology</i> , 2020, 19, 582-590.	4.9	123
72	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. <i>Circulation</i> , 2020, 142, 621-642.	1.6	232

#	ARTICLE	IF	CITATIONS
73	Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2532-2540.	1.8	18
74	<i>PPARA</i> Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. <i>Diabetes</i> , 2020, 69, 771-783.	0.3	28
75	Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. <i>European Journal of Heart Failure</i> , 2020, 22, 1133-1143.	2.9	16
76	Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trials. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 557-558.	5.5	2
77	Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. <i>Diabetes Care</i> , 2020, 43, 2242-2247.	4.3	11
78	Accumulation of Deficits as a Key Risk Factor for Cardiovascular Morbidity and Mortality: A Pooled Analysis of 154,000 Individuals. <i>Journal of the American Heart Association</i> , 2020, 9, e014686.	1.6	56
79	Dulaglutide slows kidney disease in type 2 diabetes – Author's reply. <i>Lancet</i> , 2020, 395, 559-560.	6.3	0
80	Influence of Genetic Ancestry on Human Serum Proteome. <i>American Journal of Human Genetics</i> , 2020, 106, 303-314.	2.6	19
81	Identification of Circulating Proteins Associated With Blood Pressure Using Mendelian Randomization. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002605.	1.6	8
82	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 843-862.	1.6	62
83	Adolescent Obesity and Early-Onset Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 1487-1495.	4.3	84
84	356-OR: Effect of Dulaglutide on Kidney Function-Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial. <i>Diabetes</i> , 2020, 69, 356-OR.	0.3	2
85	924-P: Exploring Potential Mediators of the Cardiovascular Benefit of Dulaglutide in REWIND. <i>Diabetes</i> , 2020, 69, 924-P.	0.3	1
86	ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study. <i>Diabetes Care</i> , 2020, 43, 835-842.	4.3	28
87	Effects of lifelong testosterone exposure on health and disease using Mendelian randomization. <i>ELife</i> , 2020, 9, .	2.8	32
88	130-OR: Effects of Intensive Risk Factor Management on Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: Findings from the ACCORD Trial. <i>Diabetes</i> , 2020, 69, 130-OR.	0.3	0
89	944-P: HbA1c Change Is Associated with Retinopathy Outcomes during GLP-1RA CVOT Follow-Up. <i>Diabetes</i> , 2020, 69, .	0.3	1
90	1421-P: The Impact of Blood Pressure on Risk of Death Is Influenced by Prior Cardiovascular Disease in Patients with Type 2 Diabetes and a Recent Coronary Event. <i>Diabetes</i> , 2020, 69, .	0.3	0

#	ARTICLE	IF	CITATIONS
91	Identification of Novel Causal Blood Biomarkers Linking Metabolically Favorable Adiposity With Type 2 Diabetes Risk. <i>Diabetes Care</i> , 2019, 42, 1800-1808.	4.3	12
92	Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics. <i>Endocrinology &amp; Diabetes Y Nutrici3n (English Ed )</i> , 2019, 66, 467-468.	0.1	0
93	The importance of randomised vs non-randomised trials “ Authors' reply. <i>Lancet, The</i> , 2019, 394, 635.	6.3	7
94	Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1299-1304.	2.2	36
95	The Cardiovascular Legacy of Good Glycemic Control: Clues About Mediators From the DCCT/EDIC Study. <i>Diabetes Care</i> , 2019, 42, 1159-1161.	4.3	13
96	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 121-130.	6.3	1,625
97	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 131-138.	6.3	394
98	Vascular Regenerative Cell Exhaustion in Diabetes: Translational Opportunities to Mitigate Cardiometabolic Risk. <i>Trends in Molecular Medicine</i> , 2019, 25, 640-655.	3.5	19
99	Dysglycemia and the Density of the Coronary Vasa Vasorum. <i>Diabetes Care</i> , 2019, 42, 980-982.	4.3	19
100	Effects of basal insulin glargine and omega-3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1502-1505.	2.2	3
101	Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. <i>Nature Metabolism</i> , 2019, 1, 1202-1208.	5.1	181
102	The association of basal insulin treatment versus standard care with outcomes in anti-GAD positive and negative subjects: A post-hoc analysis of the ORIGIN trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 429-433.	2.2	5
103	Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trial. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 847-854.	0.8	11
104	Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial. <i>Diabetes Care</i> , 2019, 42, 142-147.	4.3	18
105	Insulin use for type 2 diabetes: the challenges of predicting trends and modelling care. <i>Lancet Diabetes and Endocrinology,the</i> , 2019, 7, 4-5.	5.5	0
106	Real-world studies no substitute for RCTs in establishing efficacy. <i>Lancet, The</i> , 2019, 393, 210-211.	6.3	78
107	A Mendelian Randomization-Based Approach to Identify Early and Sensitive Diagnostic Biomarkers of Disease. <i>Clinical Chemistry</i> , 2019, 65, 427-436.	1.5	16
108	The Diabetes Health Coaching Randomized Controlled Trial: Rationale, Design and Baseline Characteristics of Adults Living With Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2019, 43, 477-482.	0.4	7

#	ARTICLE	IF	CITATIONS
109	240-LB: Angiotensin-Converting Enzyme and Type 2 Diabetes Risk: A Mendelian Randomization Study. <i>Diabetes</i> , 2019, 68, 240-LB.	0.3	0
110	1506-P: Breast Cancer as a Risk Factor for New Diabetes. <i>Diabetes</i> , 2019, 68, .	0.3	0
111	254-OR: Novel Biomarkers Predicting Renal Dysfunction in People with Dysglycemia in the ORIGIN Trial. <i>Diabetes</i> , 2019, 68, .	0.3	0
112	Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics. <i>Endocrinologia, Diabetes Y Nutrici3n</i> , 2019, 66, 467-468.	0.1	0
113	Blood HER2 and Uromodulin as Causal Mediators of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1326-1335.	3.0	21
114	Do sulphonylureas still have a place in clinical practice?. <i>Lancet Diabetes and Endocrinology</i> , the, 2018, 6, 821-832.	5.5	83
115	Newly diagnosed type 2 diabetes may serve as a potential marker for pancreatic cancer. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e3018.	1.7	7
116	The Genetic Link Between Diabetes and Atherosclerosis. <i>Canadian Journal of Cardiology</i> , 2018, 34, 565-574.	0.8	15
117	Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. <i>JAMA Cardiology</i> , 2018, 3, 225.	3.0	526
118	Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization. <i>Circulation</i> , 2018, 137, 88-90.	1.6	30
119	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a <i>Diabetes Care</i> Editorsâ€™ Expert Forum. <i>Diabetes Care</i> , 2018, 41, 14-31.	4.3	338
120	Item reduction and validation of the Chinese version of diabetes quality-of-life measure (DQOL). <i>Health and Quality of Life Outcomes</i> , 2018, 16, 78.	1.0	20
121	Insulin resistance and cardiovascular outcomes in the <scp>ORIGIN</scp> trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 564-570.	2.2	10
122	Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. <i>American Heart Journal</i> , 2018, 199, 170-175.	1.2	5
123	Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. <i>Diabetes Care</i> , 2018, 41, 348-355.	4.3	16
124	Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 97-116.	1.2	5
125	Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-9.	1.0	26
126	Cognitive function in adolescence and the risk for premature diabetes and cardiovascular mortality in adulthood. <i>Cardiovascular Diabetology</i> , 2018, 17, 154.	2.7	37



#	ARTICLE	IF	CITATIONS
127	Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. <i>Diabetes Care</i> , 2018, 41, 2404-2413.	4.3	32
128	A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks. <i>Diabetes Care</i> , 2018, 41, 1121-1124.	4.3	43
129	Minimally important difference and predictors of change in quality of life in type 2 diabetes: A community-based survey in China. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e3053.	1.7	4
130	Association of preoperative glucose concentration with myocardial injury and death after non-cardiac surgery (GlucoVISION): a prospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 790-797.	5.5	24
131	In high-risk T1DM, real-time continuous glucose monitoring vs self-monitoring reduced hypoglycemic events. <i>Annals of Internal Medicine</i> , 2018, 168, JC53.	2.0	0
132	Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 300-310.	1.2	69
133	Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 798-808.	5.5	116
134	Design and baseline characteristics of participants in the Researching cardiovascular events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 42-49.	2.2	160
135	Neighborhood Walkability and Diabetes-Related Complications. <i>Diabetes</i> , 2018, 67, 309-OR.	0.3	2
136	Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. <i>Annals of Clinical Psychiatry</i> , 2018, 30, 38-50.	0.6	28
137	Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> 2016;39:1186-1201. <i>Diabetes Care</i> , 2017, 40, e23-e24.	4.3	1
138	The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 345-352.	0.9	3
139	Systematic review: Can non-mydratic cameras accurately detect diabetic retinopathy?. <i>Diabetes Research and Clinical Practice</i> , 2017, 129, 154-159.	1.1	13
140	Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1596-1605.	1.8	38
141	The Relationship Between the Score on a Simple Measure of Cognitive Function and Incident CVD in People With Diabetes: A Post Hoc Epidemiological Analysis From the ACCORD-MIND Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3218-3225.	1.8	8
142	Influence of depression on genetic predisposition to type 2 diabetes in a multiethnic longitudinal study. <i>Scientific Reports</i> , 2017, 7, 1629.	1.6	5
143	Role of Natriuretic Peptide and N-terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	75
144	Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 431-437.	5.5	379

#	ARTICLE	IF	CITATIONS
145	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2017, 2, 370.	3.0	136
146	Growth Differentiation Factor 15 as a Novel Biomarker for Metformin. <i>Diabetes Care</i> , 2017, 40, 280-283.	4.3	112
147	Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 136, 1560-1562.	1.6	15
148	Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. <i>American Journal of Medicine</i> , 2017, 130, 1465.e27-1465.e39.	0.6	17
149	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 877-886.	5.5	245
150	Microvascular outcomes in type 2 diabetes – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 580.	5.5	0
151	Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial. <i>Diabetes Research and Clinical Practice</i> , 2017, 132, 137-143.	1.1	0
152	Causes and consequences of gestational diabetes in South Asians living in Canada: results from a prospective cohort study. <i>CMAJ Open</i> , 2017, 5, E604-E611.	1.1	28
153	Penetrance of Polygenic Obesity Susceptibility Loci across the Body Mass Index Distribution. <i>American Journal of Human Genetics</i> , 2017, 101, 925-938.	2.6	103
154	Maturation of CGM and Glycemic Measurements Beyond HbA1c – A Turning Point in Research and Clinical Decisions. <i>Diabetes Care</i> , 2017, 40, 1611-1613.	4.3	27
155	Optimizing the methodology for measuring supraclavicular skin temperature using infrared thermography; implications for measuring brown adipose tissue activity in humans. <i>Scientific Reports</i> , 2017, 7, 11934.	1.6	19
156	ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial. <i>Diabetologia</i> , 2017, 60, 69-80.	2.9	93
157	Validation of the ORIGIN Cardiovascular Biomarker Panel and the Value of Adding Troponin I in Dysglycemic People. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2251-2257.	1.8	13
158	Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response. <i>Frontiers in Genetics</i> , 2016, 7, 138.	1.1	2
159	Telomere Length and Risk of Myocardial Infarction in a MultiEthnic Population. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1863-1865.	1.2	19
160	Cardiometabolic Health in Adults Born Premature With Extremely Low Birth Weight. <i>Pediatrics</i> , 2016, 138, .	1.0	91
161	Making a Difference With Diabetes Research and Care: Table 1. <i>Diabetes Care</i> , 2016, 39, 1309-1310.	4.3	1
162	Toward Fairness in Data Sharing. <i>New England Journal of Medicine</i> , 2016, 375, 405-407.	13.9	120

#	ARTICLE	IF	CITATIONS
163	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors'™ Expert Forum. <i>Diabetes Care</i> , 2016, 39, 1186-1201.	4.3	113
164	Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. <i>Diabetes Care</i> , 2016, 39, 1915-1924.	4.3	47
165	Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study. <i>Scientific Reports</i> , 2016, 6, 18672.	1.6	62
166	Longitudinal relationships between glycemic status and body mass index in a multiethnic study: evidence from observational and genetic epidemiology. <i>Scientific Reports</i> , 2016, 6, 30744.	1.6	5
167	BMI at Age 17 Years and Diabetes Mortality in Midlife: A Nationwide Cohort of 2.3 Million Adolescents. <i>Diabetes Care</i> , 2016, 39, 1996-2003.	4.3	69
168	Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. <i>Diabetes Care</i> , 2016, 39, 1089-1100.	4.3	119
169	Self-Perceived Emotional Distress and Diabetes Risk Among Young Men. <i>American Journal of Preventive Medicine</i> , 2016, 50, 737-745.	1.6	4
170	Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. <i>Diabetes Care</i> , 2016, 39, 701-708.	4.3	150
171	Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study. <i>Diabetes Care</i> , 2016, 39, 780-787.	4.3	138
172	Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). <i>Diabetes Care</i> , 2016, 39, 709-716.	4.3	55
173	What accounts for ethnic differences in newborn skinfold thickness comparing South Asians and White Caucasians? Findings from the START and FAMILY Birth Cohorts. <i>International Journal of Obesity</i> , 2016, 40, 239-244.	1.6	30
174	Sleep quality and risk of diabetes and coronary artery disease among young men. <i>Acta Diabetologica</i> , 2016, 53, 261-270.	1.2	15
175	Comment on Hempe et al. The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. <i>Diabetes Care</i> 2015;38:1067-1074. <i>Diabetes Care</i> , 2015, 38, e170-e171.	4.3	13
176	The Relationship between Intramuscular Adipose Tissue, Functional Mobility, and Strength in Postmenopausal Women with and without Type 2 Diabetes. <i>Journal of Aging Research</i> , 2015, 2015, 1-9.	0.4	8
177	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7.	1.2	88
178	Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2682-2689.	1.8	7
179	Cognitive Performance at Late Adolescence and the Risk for Impaired Fasting Glucose Among Young Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4409-4416.	1.8	17
180	Association Between Shortened Leukocyte Telomere Length and Cardiometabolic Outcomes. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 82-90.	5.1	277

#	ARTICLE	IF	CITATIONS
181	Predictors of Nonsevere and Severe Hypoglycemia During Glucose-Lowering Treatment With Insulin Glargine or Standard Drugs in the ORIGIN Trial. <i>Diabetes Care</i> , 2015, 38, 22-28.	4.3	64
182	Dysglycaemia as a cause of cardiovascular outcomes. <i>Nature Reviews Endocrinology</i> , 2015, 11, 508-510.	4.3	26
183	Risk Prediction for Early CKD in Type 2 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1371-1379.	2.2	97
184	Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. <i>European Heart Journal</i> , 2015, 36, 1454-1462.	1.0	106
185	Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. <i>American Heart Journal</i> , 2015, 170, 117-122.	1.2	27
186	Effects of intensive glycaemic control on ischaemic heart disease – Authors' reply. <i>Lancet</i> , The, 2015, 385, 1180-1181.	6.3	0
187	Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. <i>Diabetes Care</i> , 2015, 38, 793-800.	4.3	104
188	Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. <i>American Journal of Hypertension</i> , 2015, 28, 995-1009.	1.0	18
189	Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. <i>Biochemical Journal</i> , 2015, 468, 125-132.	1.7	132
190	Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a systematic review and meta-analysis with evidence from up to 331 175 individuals. <i>Human Molecular Genetics</i> , 2015, 24, 3582-3594.	1.4	53
191	Antenatal exposure to the selective serotonin reuptake inhibitor fluoxetine leads to postnatal metabolic and endocrine changes associated with type 2 diabetes in Wistar rats. <i>Toxicology and Applied Pharmacology</i> , 2015, 285, 32-40.	1.3	18
192	Lack of association between type 2 diabetes and major depression: epidemiologic and genetic evidence in a multiethnic population. <i>Translational Psychiatry</i> , 2015, 5, e618-e618.	2.4	32
193	Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia. <i>Circulation</i> , 2015, 132, 2297-2304.	1.6	64
194	Coronary artery disease risk among obese metabolically healthy young men. <i>European Journal of Endocrinology</i> , 2015, 173, 305-312.	1.9	23
195	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2015, 373, 2247-2257.	13.9	1,856
196	Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. <i>Kidney International</i> , 2015, 87, 784-791.	2.6	86
197	Obesity Genes and Risk of Major Depressive Disorder in a Multiethnic Population. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1611-e1618.	1.1	36
198	Evaluating the Feasibility and Impact of an Internet-Based Lifestyle Management Program in a Diabetes Care Setting. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 358-362.	2.4	9

#	ARTICLE	IF	CITATIONS
199	The Cross-sectional and Longitudinal Associations of Diabetic Retinopathy With Cognitive Function and Brain MRI Findings: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>Diabetes Care</i> , 2014, 37, 3244-3252.	4.3	62
200	Response to Zanders et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. <i>Diabetes Care</i> 2014;37:1360-1366. <i>Diabetes Care</i> , 2014, 37, e223-e223.	4.3	0
201	Response to Suissa and Azoulay. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. <i>Diabetes Care</i> 2014;37:1360-1366. <i>Diabetes Care</i> , 2014, 37, e217-e217.	4.3	1
202	Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a substudy of the DREAM trial. <i>Diabetic Medicine</i> , 2014, 31, 1086-1092.	1.2	33
203	Willingness to take drugs to prevent serious chronic diseases (e.g., diabetes, hypertension, hyperlipidemia, etc.). <i>Journal of Diabetes Care</i> , 2014, 37, 1086-1092.		
204	White blood cell subtypes, insulin resistance and beta cell dysfunction in high-risk individuals: the PROMISE cohort. <i>Clinical Endocrinology</i> , 2014, 81, 536-541.	1.2	41
205	Cognitive Function and Brain Structure in Persons With Type 2 Diabetes Mellitus After Intensive Lowering of Blood Pressure and Lipid Levels. <i>JAMA Internal Medicine</i> , 2014, 174, 324.	2.6	142
206	Cognitive Function and the Risk for Diabetes Among Young Men. <i>Diabetes Care</i> , 2014, 37, 2982-2988.	4.3	56
207	Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI. <i>Diabetologia</i> , 2014, 57, 738-745.	2.9	9
208	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. <i>European Heart Journal</i> , 2014, 35, 2242-2248.	1.0	42
209	Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial. <i>Diabetes Care</i> , 2014, 37, 1721-1728.	4.3	217
210	Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. <i>Diabetologia</i> , 2014, 57, 1325-1331.	2.9	47
211	Effect of Hypoglycemia on Brain Structure in People With Type 2 Diabetes: Epidemiological Analysis of the ACCORD-MIND MRI Trial. <i>Diabetes Care</i> , 2014, 37, 3279-3285.	4.3	18
212	Does genetic heterogeneity account for the divergent risk of type 2 diabetes in South Asian and white European populations?. <i>Diabetologia</i> , 2014, 57, 2270-2281.	2.9	29
213	Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. <i>Lancet</i> , 2014, 384, 1936-1941.	6.3	134
214	Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial. <i>Diabetologia</i> , 2014, 57, 2030-2037.	2.9	10
215	The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. <i>Diabetes Care</i> , 2014, 37, 1360-1366.	4.3	76
216	Does a Patient-Managed Insulin Intensification Strategy With Insulin Glargine and Insulin Glulisine Provide Similar Glycemic Control as a Physician-Managed Strategy? Results of the START (Self-Titration) Trial. <i>Diabetes Care</i> , 2014, 37, 1360-1366.		

#	ARTICLE	IF	CITATIONS
217	Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial. <i>Diabetes Care</i> , 2014, 37, 634-643.	4.3	104
218	Metabolic effects of telmisartan in subjects with abdominal obesity: A prospective randomized controlled trial. <i>Blood Pressure</i> , 2014, 23, 54-60.	0.7	8
219	Diabetes Risk Among Overweight and Obese Metabolically Healthy Young Adults. <i>Diabetes Care</i> , 2014, 37, 2989-2995.	4.3	100
220	Cost implications of the use of basal insulin glargine in people with early dysglycemia: The ORIGIN trial. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 553-558.	1.2	13
221	Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. <i>American Heart Journal</i> , 2014, 168, 23-29.e2.	1.2	50
222	Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 843-851.	5.5	260
223	Writing science that your colleagues can read. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 4-5.	1.2	1
224	Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: A subanalysis of the ORIGIN trial. <i>International Journal of Cardiology</i> , 2014, 174, 458-461.	0.8	83
225	Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 562-572.	5.5	52
226	Prospective association of 25(OH)D with metabolic syndrome. <i>Clinical Endocrinology</i> , 2014, 80, 502-507.	1.2	44
227	Myocardial Injury after Noncardiac Surgery. <i>Anesthesiology</i> , 2014, 120, 564-578.	1.3	740
228	Changes in trabecular bone microarchitecture in postmenopausal women with and without type 2 diabetes: a two year longitudinal study. <i>BMC Musculoskeletal Disorders</i> , 2013, 14, 114.	0.8	24
229	Can community retail pharmacist and diabetes expert support facilitate insulin initiation by family physicians? Results of the AIM@GP randomized controlled trial. <i>BMC Health Services Research</i> , 2013, 13, 71.	0.9	14
230	Setting the record straight on TIDE: a lost opportunity for patients with diabetes. <i>Diabetologia</i> , 2013, 56, 1884-1887.	2.9	2
231	Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-Risk Multiethnic Population. <i>Diabetes Care</i> , 2013, 36, 2836-2842.	4.3	22
232	The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression. <i>Molecular Psychiatry</i> , 2013, 18, 1281-1286.	4.1	115
233	Hyperglycaemia is associated with impaired vasa vasorum neovascularization and accelerated atherosclerosis in apolipoprotein-E deficient mice. <i>Atherosclerosis</i> , 2013, 227, 250-258.	0.4	30
234	Rosiglitazone and Cardiovascular Outcomes. <i>Circulation</i> , 2013, 128, 777-779.	1.6	2

#	ARTICLE	IF	CITATIONS
235	Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 71-78.	5.5	39
236	Increased cardiovascular risk after pre-eclampsia in women with dysglycaemia. <i>Diabetic Medicine</i> , 2013, 30, e1-7.	1.2	14
237	Do Lifestyle Changes Reduce Serious Outcomes in Diabetes?. <i>New England Journal of Medicine</i> , 2013, 369, 189-190.	13.9	40
238	Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial. <i>Diabetes Care</i> , 2013, 36, 2162-2168.	4.3	46
239	Association of Depression With Accelerated Cognitive Decline Among Patients With Type 2 Diabetes in the ACCORD-MIND Trial. <i>JAMA Psychiatry</i> , 2013, 70, 1041.	6.0	114
240	Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. <i>European Heart Journal</i> , 2013, 34, 3137-3144.	1.0	211
241	Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. <i>Diabetes Care</i> 2013;36:2915-2922. <i>Diabetes Care</i> , 2013, 36, e181-e181.	4.3	1
242	Short Leg Length, a Marker of Early Childhood Deprivation, Is Associated With Metabolic Disorders Underlying Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3599-3606.	4.3	26
243	Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events. <i>Diabetes Care</i> , 2013, 36, 2466-2474.	4.3	40
244	Postnatal Metabolic and Reproductive Consequences of Fetal and Neonatal Exposure to the Smoking Cessation Drug Bupropion. <i>Reproductive Sciences</i> , 2013, 20, 1156-1161.	1.1	11
245	Diabetic Retinopathy, Its Progression, and Incident Cardiovascular Events in the ACCORD Trial. <i>Diabetes Care</i> , 2013, 36, 1266-1271.	4.3	86
246	Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes. <i>Journal of Hypertension</i> , 2013, 31, 414-421.	0.3	72
247	Causal Relationship between Adiponectin and Metabolic Traits: A Mendelian Randomization Study in a Multiethnic Population. <i>PLoS ONE</i> , 2013, 8, e66808.	1.1	57
248	Poor Cognitive Function and Risk of Severe Hypoglycemia in Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 787-793.	4.3	291
249	Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes: An analysis of baseline data from the ORIGIN trial. <i>Diabetes Care</i> , 2012, 35, 749-753.	4.3	23
250	Glycemic Index Predicts Individual Glucose Responses after Self-Selected Breakfasts in Free-Living, Abdominally Obese Adults. <i>Journal of Nutrition</i> , 2012, 142, 27-32.	1.3	15
251	Basal Insulin and Cardiovascular and Other Outcomes. <i>New England Journal of Medicine</i> , 2012, 367, 1761-1764.	13.9	12
252	Maternal antioxidants prevent $\beta$ -cell apoptosis and promote formation of dual hormone-expressing endocrine cells in male offspring following fetal and neonatal nicotine exposure. <i>Journal of Diabetes</i> , 2012, 4, 297-306.	0.8	16

#	ARTICLE	IF	CITATIONS
253	Piloting a Novel Algorithm for Glucose Control in the Coronary Care Unit. <i>Diabetes Care</i> , 2012, 35, 19-24.	4.3	15
254	Is regression to normoglycaemia clinically important?. <i>Lancet, The</i> , 2012, 379, 2216-2218.	6.3	11
255	Combined intensive blood pressure and glycaemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. <i>Kidney International</i> , 2012, 81, 586-594.	2.6	53
256	nâ€“3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. <i>New England Journal of Medicine</i> , 2012, 367, 309-318.	13.9	810
257	Impact of a computerized system for evidence-based diabetes care on completeness of records: a beforeâ€“after study. <i>BMC Medical Informatics and Decision Making</i> , 2012, 12, 63.	1.5	9
258	Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. <i>Respiratory Medicine</i> , 2012, 106, 1487-1493.	1.3	77
259	Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 755-764.	0.8	74
260	Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. <i>New England Journal of Medicine</i> , 2012, 367, 319-328.	13.9	1,426
261	Randomized trial of insulin versus usual care in reducing restenosis after coronary intervention in patients with diabetes. the STent Restenosis And Metabolism (STREAM) study. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 95-100.	0.3	13
262	Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. <i>International Journal of Clinical Practice</i> , 2012, 66, 457-464.	0.8	37
263	Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. <i>Diabetologia</i> , 2012, 55, 36-45.	2.9	56
264	Association of 25(OH)D and PTH with Metabolic Syndrome and Its Traditional and Nontraditional Components. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 168-175.	1.8	107
265	Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. <i>New England Journal of Medicine</i> , 2011, 364, 818-828.	13.9	901
266	Effect of combining rosiglitazone with either metformin or insulin on Î²-cell mass and function in an animal model of Type 2 diabetes characterized by reduced Î²-cell mass at birth. <i>Journal of Diabetes</i> , 2011, 3, 74-81.	0.8	3
267	Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population. <i>Journal of Diabetes</i> , 2011, 3, 232-237.	0.8	6
268	Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. <i>Lancet Neurology, The</i> , 2011, 10, 969-977.	4.9	455
269	Establishing a relationship between prolactin and altered fatty acid Î²-Oxidation via carnitine palmitoyl transferase 1 in breast cancer cells. <i>BMC Cancer</i> , 2011, 11, 56.	1.1	65
270	Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada. <i>Quality of Life Research</i> , 2011, 20, 939-943.	1.5	44



#	ARTICLE	IF	CITATIONS
271	Dysglycaemia, dyslipidaemia and hypertension: risk factors primarily focused on the disease or risk estimates primarily focused on the patient?. <i>Diabetologia</i> , 2011, 54, 230-232.	2.9	5
272	Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. <i>Diabetologia</i> , 2011, 54, 487-495.	2.9	48
273	Computerized clinical decision support systems for chronic disease management: A decision-maker-researcher partnership systematic review. <i>Implementation Science</i> , 2011, 6, 92.	2.5	183
274	A community-based approach for the self-management of diabetes. <i>European Diabetes Nursing</i> , 2011, 8, 54-59.	0.2	1
275	Long-Acting Risperidone and Oral Antipsychotics in Schizophrenia. <i>New England Journal of Medicine</i> , 2011, 364, 2264-2266.	13.9	1
276	Shared Electronic Vascular Risk Decision Support in Primary Care. <i>Archives of Internal Medicine</i> , 2011, 171, 1736.	4.3	37
277	Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal. <i>Diabetes Care</i> , 2011, 34, 1265-1269.	4.3	30
278	Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. <i>European Heart Journal</i> , 2011, 32, 581-589.	1.0	199
279	Effect of Computer-Generated Tailored Feedback on Glycemic Control in People With Diabetes in the Community. <i>Diabetes Care</i> , 2011, 34, 1794-1798.	4.3	12
280	Serious Cardiovascular Outcomes in Diabetes. <i>Circulation</i> , 2011, 123, 342-348.	1.6	93
281	Prospective Associations of Vitamin D With $\beta$ -Cell Function and Glycemia. <i>Diabetes</i> , 2011, 60, 2947-2953.	0.3	124
282	Adipocyte Hypertrophy, Fatty Liver and Metabolic Risk Factors in South Asians: The Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE). <i>PLoS ONE</i> , 2011, 6, e22112.	1.1	128
283	Low-Dose Combination Therapy With Rosiglitazone And Metformin to Prevent Type 2 Diabetes Mellitus (CANOE Trial): A Double-Blind Randomized Controlled Study. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 771-772.	0.2	1
284	Lack of Association Between Thiazolidinediones and Macular Edema in Type 2 Diabetes. <i>JAMA Ophthalmology</i> , 2010, 128, 312.	2.6	50
285	Anthropometric measures and glucose levels in a large multi-ethnic cohort of individuals at risk of developing type 2 diabetes. <i>Diabetologia</i> , 2010, 53, 1322-1330.	2.9	29
286	Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. <i>Diabetologia</i> , 2010, 53, 2509-2517.	2.9	52
287	Rosiglitazone improves pancreatic mitochondrial function in an animal model of dysglycemia: role of the insulin-like growth factor axis. <i>Endocrine</i> , 2010, 37, 303-311.	1.1	6
288	Kidney Disease After Preeclampsia: A Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2010, 55, 1026-1039.	2.1	177

#	ARTICLE	IF	CITATIONS
289	Analysis of Health Utility Data When Some Subjects Attain the Upper Bound of 1: Are Tobit and CLAD Models Appropriate?. <i>Value in Health</i> , 2010, 13, 487-494.	0.1	120
290	Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. <i>Diabetic Medicine</i> , 2010, 27, 175-180.	1.2	40
291	Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. <i>Diabetic Medicine</i> , 2010, 27, 1226-1232.	1.2	15
292	Ethnic Variation in Adiponectin and Leptin Levels and Their Association With Adiposity and Insulin Resistance. <i>Diabetes Care</i> , 2010, 33, 1629-1634.	4.3	152
293	Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>Diabetes Care</i> , 2010, 33, 1578-1584.	4.3	435
294	Response to Letter Regarding Article, "Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction". <i>Circulation</i> , 2010, 122, .	1.6	0
295	A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs. <i>Diabetes Care</i> , 2010, 33, 1176-1178.	4.3	145
296	Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2010, 121, 1176-1187.	1.6	95
297	Macular Edema and Thiazolidinediones"Reply. <i>JAMA Ophthalmology</i> , 2010, 128, 1631.	2.6	0
298	Does Insulin Therapy Promote, Reduce, or Have a Neutral Effect on Cancers?. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 446.	3.8	56
299	Long-Term Consequences of Fetal and Neonatal Nicotine Exposure: A Critical Review. <i>Toxicological Sciences</i> , 2010, 116, 364-374.	1.4	307
300	Effect of Rosiglitazone and Ramipril on $\beta$ -Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose: The DREAM trial. <i>Diabetes Care</i> , 2010, 33, 608-613.	4.3	50
301	Variation at the <i>NFATC2</i> Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. <i>Diabetes Care</i> , 2010, 33, 2250-2253.	4.3	34
302	Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2010, 362, 1575-1585.	13.9	3,117
303	Association of Vitamin D With Insulin Resistance and $\beta$ -Cell Dysfunction in Subjects at Risk for Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 1379-1381.	4.3	287
304	The Effect of Oral Antidiabetic Agents on A1C Levels. <i>Diabetes Care</i> , 2010, 33, 1859-1864.	4.3	275
305	Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2010, 363, 233-244.	13.9	1,091
306	The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. <i>BMJ: British Medical Journal</i> , 2010, 340, b5444-b5444.	2.4	359

#	ARTICLE	IF	CITATIONS
307	Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2010, 362, 1563-1574.	13.9	2,460
308	Metabolic Syndrome and Risk of Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2390-2398.	1.2	197
309	Clinical outcomes trials and the cardiovascular effects of thiazolidinediones: Implications for the evaluation of antidiabetic drugs. <i>American Heart Journal</i> , 2010, 160, 1-2.	1.2	20
310	Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. <i>Lancet</i> , The, 2010, 376, 103-111.	6.3	216
311	More insights on the dysglycaemiaâ€“cardiovascular connection. <i>Lancet</i> , The, 2010, 375, 2195-2196.	6.3	29
312	Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. <i>Canadian Journal of Cardiology</i> , 2010, 26, 297-302.	0.8	89
313	Relationship Between Baseline Glycemic Control and Cognitive Function in Individuals With Type 2 Diabetes and Other Cardiovascular Risk Factors. <i>Diabetes Care</i> , 2009, 32, 221-226.	4.3	387
314	Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample. <i>Journal of Lipid Research</i> , 2009, 50, 1487-1496.	2.0	54
315	Dysglycemia and Cardiovascular Risk in the General Population. <i>Circulation</i> , 2009, 119, 773-775.	1.6	23
316	Is it possible to reduce cardiovascular risk with glucose-lowering approaches?. <i>Nature Reviews Endocrinology</i> , 2009, 5, 270-275.	4.3	10
317	Individualized electronic decision support and reminders to improve diabetes care in the community: COMPETE II randomized trial. <i>Cmaj</i> , 2009, 181, 37-44.	0.9	179
318	Association of Hematological Parameters with Insulin Resistance and Î²-Cell Dysfunction in Nondiabetic Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3824-3832.	1.8	69
319	Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction. <i>Circulation</i> , 2009, 120, 2429-2437.	1.6	121
320	Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. <i>Diabetes Care</i> , 2009, 32, 915-920.	4.3	61
321	Effects of rosiglitazone on ovarian function and fertility in animals with reduced fertility following fetal and neonatal exposure to nicotine. <i>Endocrine</i> , 2009, 36, 281-290.	1.1	29
322	Intensive glucose control and macrovascular outcomes in type 2 diabetes. <i>Diabetologia</i> , 2009, 52, 2288-2298.	2.9	1,033
323	Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: Results from the ONTARGET/TRANSCEND Research Programme. <i>Diabetes Research and Clinical Practice</i> , 2009, 83, 387-393.	1.1	26
324	Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. <i>American Heart Journal</i> , 2009, 157, 763-770.	1.2	28

#	ARTICLE	IF	CITATIONS
325	Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2028-2035.	1.2	54
326	Albuminuria in chronic heart failure: prevalence and prognostic importance. <i>Lancet</i> , 2009, 374, 543-550.	6.3	239
327	Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 763-771.	2.2	23
328	Maternal nicotine exposure increases oxidative stress in the offspring. <i>Free Radical Biology and Medicine</i> , 2008, 44, 1919-1925.	1.3	81
329	Effects of Intensive Glucose Lowering in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2008, 358, 2545-2559.	13.9	7,084
330	Relationship of epicardial fat thickness and fasting glucose. <i>International Journal of Cardiology</i> , 2008, 128, 424-426.	0.8	93
331	Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Tj ETQq1 1 0.784314 rgB7i/Over	1.0	14
332	Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): Study design and baseline characteristics. <i>American Heart Journal</i> , 2008, 156, 1074-1079.	1.2	19
333	Dysglycemia and a History of Reproductive Risk Factors. <i>Diabetes Care</i> , 2008, 31, 1635-1638.	4.3	23
334	Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points. <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 276-284.	0.9	8
335	The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure. <i>Archives of Internal Medicine</i> , 2008, 168, 1699.	4.3	194
336	Increased Pancreatic Beta-Cell Apoptosis following Fetal and Neonatal Exposure to Nicotine Is Mediated via the Mitochondria. <i>Toxicological Sciences</i> , 2008, 103, 362-370.	1.4	65
337	Fetal and Neonatal Nicotine Exposure in Wistar Rats Causes Progressive Pancreatic Mitochondrial Damage and Beta Cell Dysfunction. <i>PLoS ONE</i> , 2008, 3, e3371.	1.1	68
338	Can family physicians help patients initiate basal insulin therapy successfully?: randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. <i>Canadian Family Physician</i> , 2008, 54, 550-8.	0.1	26
339	Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 798-799.	2.9	2
340	Fetal and neonatal nicotine exposure and postnatal glucose homeostasis: identifying critical windows of exposure. <i>Journal of Endocrinology</i> , 2007, 194, 171-178.	1.2	73
341	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. <i>Circulation</i> , 2007, 115, 114-126.	1.6	634
342	Point: If It Is Important to Prevent Type 2 Diabetes, It Is Important to Consider All Proven Therapies Within a Comprehensive Approach. <i>Diabetes Care</i> , 2007, 30, 432-434.	4.3	15

#	ARTICLE	IF	CITATIONS
343	Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: The Canadian INSIGHT Study. <i>Diabetes Research and Clinical Practice</i> , 2007, 78, 254-258.	1.1	53
344	Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia. <i>Diabetes Research and Clinical Practice</i> , 2007, 78, 392-397.	1.1	36
345	Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: A systematic overview and meta-analysis of prospective studies. <i>Diabetes Research and Clinical Practice</i> , 2007, 78, 305-312.	1.1	471
346	Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk. <i>Circulation</i> , 2007, 115, 1371-1375.	1.6	180
347	The effects of exercise training on insulin resistance in patients with coronary artery disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007, 14, 803-808.	3.1	8
348	A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin. <i>Diabetes Care</i> , 2007, 30, 389-394.	4.3	280
349	Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: a systematic review. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 1180-5.	1.4	83
350	Dysglycemia in a community sample of people treated for schizophrenia: The Diabetes in Schizophrenia in Central-south Ontario (DiSCO) study. <i>Schizophrenia Research</i> , 2007, 96, 215-222.	1.1	34
351	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. <i>Diabetes Care</i> , 2007, 30, 162-172.	4.3	577
352	A Family-based Intervention to Promote Healthy Lifestyles in an Aboriginal Community in Canada. <i>Canadian Journal of Public Health</i> , 2007, 98, 447-452.	1.1	72
353	Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>American Journal of Cardiology</i> , 2007, 99, S4-S20.	0.7	189
354	Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods. <i>American Journal of Cardiology</i> , 2007, 99, S21-S33.	0.7	491
355	Glycemia Treatment Strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>American Journal of Cardiology</i> , 2007, 99, S34-S43.	0.7	149
356	Transgenerational effects of fetal and neonatal exposure to nicotine. <i>Endocrine</i> , 2007, 31, 254-259.	2.2	52
357	Effect of Ramipril on the Incidence of Diabetes. <i>New England Journal of Medicine</i> , 2006, 355, 1551-1562.	13.9	684
358	Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. <i>Lancet, The</i> , 2006, 368, 1096-1105.	6.3	1,564
359	The DREAM trial – Authors' reply. <i>Lancet, The</i> , 2006, 368, 2050-2051.	6.3	230
360	Preventing type 2 diabetes using combination therapy: design and methods of the CANadian Normoglycaemia Outcomes Evaluation (CANOE) trial. <i>Diabetes, Obesity and Metabolism</i> , 2006, 8, 531-537.	2.2	30

#	ARTICLE	IF	CITATIONS
361	A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia) Tj ETQq1 1 0.7843147rgBT /Overlock 10	1.2	189
362	Reply to comment on: Gerstein HC, Pogue J, Mann JFE et al. (2005) The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 48:1749â€“1755. Diabetologia, 2006, 49, 613-614.	2.9	1
363	Reevaluation by High-Performance Liquid Chromatography: Clinical Significance of Microalbuminuria in Individuals at High Risk of Cardiovascular Disease in the Heart Outcomes Prevention Evaluation (HOPE) Study. American Journal of Kidney Diseases, 2006, 48, 889-896.	2.1	25
364	Why don't pigs get diabetes? Explanations for variations in diabetes susceptibility in human populations living in a diabetogenic environment. Cmaj, 2006, 174, 25-26.	0.9	49
365	Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?. Cmaj, 2006, 174, 1090-1091.	0.9	2
366	Diabetes susceptibility. Cmaj, 2006, 174, 1598-1598.	0.9	0
367	Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation, 2006, 114, 201-208.	1.6	236
368	Intensive insulin therapy reduced cardiovascular disease in type 1 diabetes. ACP Journal Club, 2006, 144, 63.	0.1	0
369	Fetal and neonatal exposure to nicotine in Wistar rats results in increased beta cell apoptosis at birth and postnatal endocrine and metabolic changes associated with type 2 diabetes. Diabetologia, 2005, 48, 2661-2666.	2.9	120
370	Cognitive decline and dementia in diabetesâ€”systematic overview of prospective observational studies. Diabetologia, 2005, 48, 2460-2469.	2.9	852
371	The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia, 2005, 48, 1749-1755.	2.9	233
372	The Burden of Treatment Failure in Type 2 Diabetes: Response to Brown et al.. Diabetes Care, 2005, 28, 761-762.	4.3	4
373	Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure. Circulation, 2005, 112, 48-53.	1.6	211
374	Use of Inhaled Insulin in a Basal/Bolus Insulin Regimen in Type 1 Diabetic Subjects: A 6-month, randomized, comparative trial. Diabetes Care, 2005, 28, 1630-1635.	4.3	265
375	Insulin Therapy in People Who Have Dysglycemia and Type 2 Diabetes Mellitus: Can It Offer Both Cardiovascular Protection and Beta-Cell Preservation?. Endocrinology and Metabolism Clinics of North America, 2005, 34, 137-154.	1.2	21
376	Glycemia and Risk for Cardiovascular Disease. Annals of Internal Medicine, 2005, 142, 227.	2.0	0
377	Individualized electronic decision support and reminders can improve diabetes care in the community. AMIA ... Annual Symposium proceedings, 2005, , 982.	0.2	4
378	Authorsâ€™ Response: Dosage Recommendations for Combination Regimen of Thyroxine and 3,5,3â€”Triiodothyronine. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1487-1487.	1.8	1

#	ARTICLE	IF	CITATIONS
379	Glycosylated Hemoglobin: Finally Ready for Prime Time as a Cardiovascular Risk Factor. <i>Annals of Internal Medicine</i> , 2004, 141, 475.	2.0	57
380	Dosage Recommendations for Combination Regimen of Thyroxine and 3,5,3-Triiodothyronine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1486-1487.	1.8	9
381	The Effect of Vitamin E Supplementation on Cardiovascular Risk in Diabetic Individuals With Different Haptoglobin Phenotypes. <i>Diabetes Care</i> , 2004, 27, 2767-2767.	4.3	78
382	Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial. <i>Diabetic Medicine</i> , 2004, 21, 1200-1203.	1.2	10
383	Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE Study. <i>Kidney International</i> , 2004, 65, 1375-1380.	2.6	102
384	Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. <i>Kidney International</i> , 2004, 66, S59-S62.	2.6	70
385	Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. <i>Diabetologia</i> , 2004, 47, 1519-1527.	2.9	157
386	A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3668-3676.	1.8	398
387	Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. <i>American Journal of Kidney Diseases</i> , 2003, 42, 936-942.	2.1	75
388	Cardiovascular risk in patients with mild renal insufficiency. <i>Kidney International</i> , 2003, 63, S192-S196.	2.6	61
389	Acarbose in the treatment of elderly patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2003, 59, 37-42.	1.1	97
390	Development of Renal Disease in People at High Cardiovascular Risk: Results of the HOPE Randomized Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 641-647.	3.0	130
391	Diagnostic Strategies to Detect Glucose Intolerance in a Multiethnic Population. <i>Diabetes Care</i> , 2003, 26, 290-296.	4.3	70
392	The Relationship Between Dysglycemia and Atherosclerosis in South Asian, Chinese, and European Individuals in Canada: A randomly sampled cross-sectional study. <i>Diabetes Care</i> , 2003, 26, 144-149.	4.3	51
393	Does a Combination Regimen of Thyroxine (T4) and 3,5,3-Triiodothyronine Improve Depressive Symptoms Better Than T4 Alone in Patients with Hypothyroidism? Results of a Double-Blind, Randomized, Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4551-4555.	1.8	159
394	Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease. <i>Circulation</i> , 2003, 108, 420-425.	1.6	257
395	A disturbed glucose metabolic state (dysglycaemia) is a key risk factor for cardiovascular events. <i>European Heart Journal Supplements</i> , 2003, 5, B1-B2.	0.0	2
396	Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies. <i>European Heart Journal Supplements</i> , 2003, 5, A43-A48.	0.0	25

#	ARTICLE	IF	CITATIONS
397	Enalapril reduced the risk for developing new-onset diabetes in left ventricular dysfunction. ACP Journal Club, 2003, 139, 68.	0.1	0
398	Increased occurrence of diabetes in people with ischemic cardiovascular disease and general and abdominal obesity. Canadian Journal of Cardiology, 2003, 19, 1387-91.	0.8	22
399	Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes: Results of the HOPE Study and MICRO-HOPE Substudy. Diabetes Care, 2002, 25, 1919-1927.	4.3	349
400	The Economic Cost of Diabetes in Canada, 1998. Diabetes Care, 2002, 25, 1303-1307.	4.3	93
401	Dysglycemia: A Key Cardiovascular Risk Factor. Seminars in Vascular Medicine, 2002, 2, 165-174.	2.1	17
402	Epidemiologic analyses of risk factors, risk indicators, risk markers, and causal factors. Endocrinology and Metabolism Clinics of North America, 2002, 31, 537-551.	1.2	8
403	Cardiovascular Risk in Patients with Early Renal Insufficiency. American Journal of Cardiovascular Drugs, 2002, 2, 157-162.	1.0	29
404	The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas—a randomized trial. Diabetes Research and Clinical Practice, 2002, 55, 209-219.	1.1	144
405	Cardiovascular Outcomes and Renal Disease. Annals of Internal Medicine, 2002, 136, 634.	2.0	5
406	Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes/Metabolism Research and Reviews, 2002, 18, S82-S85.	1.7	70
407	The value of large, robust trials: the HOPE study. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2002, 19, 29-30.	0.2	1
408	Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). Lancet, The, 2001, 358, 1147-1153.	6.3	257
409	Reducing the Risk of Cardiovascular Complications in the Long-Term Care Setting. Journal of the American Medical Directors Association, 2001, 2, H13-H16.	1.2	0
410	Stress Hyperglycemia and Prognosis of Stroke in Nondiabetic and Diabetic Patients. Stroke, 2001, 32, 2426-2432.	1.0	1,609
411	Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial. Annals of Internal Medicine, 2001, 134, 629.	2.0	1,243
412	Ramipril and the Development of Diabetes. JAMA - Journal of the American Medical Association, 2001, 286, 1882.	3.8	487
413	Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals. JAMA - Journal of the American Medical Association, 2001, 286, 421.	3.8	2,067
414	The Plasma Glucose Level - A Continuous Risk Factor for Vascular Disease in Both Diabetic and Non-Diabetic People. Advances in Experimental Medicine and Biology, 2001, 498, 35-39.	0.8	4



#	ARTICLE	IF	CITATIONS
415	Perceived exertion with glucose ingestion in adolescent males with IDDM. <i>Medicine and Science in Sports and Exercise</i> , 2000, 32, 167.	0.2	28
416	Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. <i>Diabetes Care</i> , 2000, 23, 377-380.	4.3	38
417	The HOPE study and diabetes. <i>Lancet, The</i> , 2000, 355, 1183-1184.	6.3	19
418	Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. <i>Lancet, The</i> , 2000, 355, 773-778.	6.3	1,959
419	Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. <i>Lancet, The</i> , 2000, 355, 253-259.	6.3	3,134
420	Miglitol, an $\alpha$ -glucosidase inhibitor, prevents the metformin-induced fall in serum folate and vitamin B12 in subjects with type 2 diabetes. <i>Nutrition Research</i> , 2000, 20, 1447-1456.	1.3	19
421	Searching for answers to ethnic disparities in cardiovascular risk. <i>Lancet, The</i> , 2000, 356, 266-267.	6.3	25
422	Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). <i>Lancet, The</i> , 2000, 356, 279-284.	6.3	866
423	Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non-Q-Wave Myocardial Infarction. <i>Circulation</i> , 2000, 102, 1014-1019.	1.6	688
424	A controlled evaluation of a national continuing medical education programme designed to improve family physicians' implementation of diabetes-specific clinical practice guidelines. <i>Diabetic Medicine</i> , 1999, 16, 964-969.	1.2	31
425	Summary of Randomized Trials of Angiotensin Converting Enzyme Inhibitors. <i>Clinical and Experimental Hypertension</i> , 1999, 21, 835-845.	0.5	19
426	Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. <i>Canadian Journal of Physiology and Pharmacology</i> , 1999, 77, 118-123.	0.7	42
427	Preventive medicine in a diabetes clinic: an opportunity to make a difference. <i>Lancet, The</i> , 1999, 353, 606-608.	6.3	9
428	Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. <i>Journal of the American College of Cardiology</i> , 1999, 33, 612-619.	1.2	88
429	The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. <i>Diabetes Care</i> , 1999, 22, 233-240.	4.3	1,571
430	Dysglycaemia: a cardiovascular risk factor. <i>Diabetes Research and Clinical Practice</i> , 1998, 40, S9-S14.	1.1	14
431	Ramipril slowed the decline in renal function among patients with nephropathy and proteinuria not due to insulin-dependent diabetes mellitus. <i>Evidence-based Cardiovascular Medicine</i> , 1998, 2, 23-24.	0.0	0
432	Troglitazone Monotherapy Improves Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 3169-3176.	1.8	77

#	ARTICLE	IF	CITATIONS
433	The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators. <i>Canadian Journal of Cardiology</i> , 1998, 14, 1349-57.	0.8	29
434	Psychiatric Symptoms, Bone Density and Non-Specific Symptoms in Patients with Mild Hypercalcemia due to Primary Hyperparathyroidism: A Systematic Overview of the Literature.. <i>Endocrine Journal</i> , 1997, 44, 367-374.	0.7	43
435	Dysglycemia, not just diabetes, is a continuous risk factor for cardiovascular disease. <i>Evidence-based Cardiovascular Medicine</i> , 1997, 1, 87-88.	0.0	15
436	Risk factors for acute myocardial infarction in Indians: a case-control study. <i>Lancet, The</i> , 1996, 348, 358-363.	6.3	246
437	Dysglycaemia and risk of cardiovascular disease. <i>Lancet, The</i> , 1996, 347, 949-950.	6.3	164
438	A New Mutation in the Thyroid Hormone Receptor (TR) $\beta$ Gene (V458A) in a Family with Resistance to Thyroid Hormone (RTH). <i>Thyroid</i> , 1996, 6, 311-312.	2.4	12
439	Does treatment withl-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism?. <i>Journal of General Internal Medicine</i> , 1996, 11, 744-749.	1.3	205
440	Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study. <i>Diabetes Care</i> , 1996, 19, 1225-1228.	4.3	67
441	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1995, 273, 1610.	3.8	114
442	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1995, 274, 1800.	3.8	641
443	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1994, 271, 389.	3.8	771
444	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1994, 272, 1367.	3.8	568
445	Spectrum of quality of life impairment in hypothyroidism. <i>Quality of Life Research</i> , 1994, 3, 323-327.	1.5	68
446	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1994, 271, 59.	3.8	527
447	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1994, 271, 703.	3.8	1,710
448	Incidence of Postpartum Thyroid Dysfunction in Patients with Type I Diabetes Mellitus. <i>Annals of Internal Medicine</i> , 1993, 118, 419.	2.0	149
449	How common is postpartum thyroiditis? A methodologic overview of the literature. <i>Archives of Internal Medicine</i> , 1990, 150, 1397-1400.	4.3	30
450	Separate Induction of MHC and Thyroid Microsomal Antigen (McAg) Expression on Thyroid Cell Monolayers: Enhancement of Lectin-Induced McAg Expression by Interferon- $\gamma$ *. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987, 64, 1302-1308.	1.8	10

#	ARTICLE	IF	CITATIONS
451	IMMUNOMODULATORY EFFECT OF THE TREATMENT OF GRAVES' DISEASE ON ANTIGEN-SPECIFIC MONOCYTE PROCOAGULANT ACTIVITY PRODUCTION. <i>Clinical Endocrinology</i> , 1987, 27, 321-330.	1.2	2
452	Sensitization of T lymphocytes to thyroid antigen in autoimmune thyroid disease as demonstrated by the monocyte procoagulant activity test. <i>Journal of Endocrinological Investigation</i> , 1986, 9, 471-478.	1.8	6
453	Thyocyte HLA-DR Expression and Interferon- $\beta$ Production in Autoimmune Thyroid Disease*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986, 63, 695-708.	1.8	113
454	Prevention of the Consequences of Diabetes- a Commentary. , 0, , 266-272.		1